A division of Alnylam Pharmaceuticals.

, a leading RNAi therapeutics company, announced today the demonstration of brand-new data at the Cell Culture Engineering XII conference held in Alberta, Canada from April 25 – 30, 2010. Alnylam Biotherapeutics was created by Alnylam to develop RNAi technologies for application in manufacturing procedures for biotherapeutic products, including recombinant proteins and monoclonal antibodies. The new data offered demonstrated the ability to achieve effective delivery of siRNAs into Chinese hamster ovary cells grown in one liter suspension culture and to achieve powerful silencing of CHO sponsor gene targets involved in both cellular apoptotic and metabolic pathways. An interview with Dr Matt Silver’Our progress to date inside our Alnylam Biotherapeutics initiatives has been very significant and clearly helps the use of RNAi technologies to potentially transform manufacturing processes for biotherapeutic drugs, including their quality, volume, and attributes,’ stated Stuart Pollard, Ph.D., Vice President of Scientific and Business Technique at Alnylam.The order also contains advanced tools enabling a more efficient treatment planning process, such as Multi-Criteria optimization. Advanced ROS will start the implementation in late August with plans to be clinical in early September. Related StoriesStudy shows uncommon HER2 missense mutations usually do not spread breast cancer on their ownNew antenna-like device makes breast cancer surgery easier for surgeonsViralytics enters into medical trial collaboration agreement with MSD RayStation provides our middle with a complete and comprehensive treatment planning solution.